Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glufosfamide (Baxter Oncology).

Ion Niculescu-Duvaz1

  • 1CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK. ion@icr.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|November 15, 2002
PubMed
Summary
This summary is machine-generated.

Glufosfamide, an alkylating agent, is being developed for cancer treatment. Early trials included intrathecal administration for patients with carcinomatous meningioma.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.

Bioorganic & medicinal chemistry·2013
Same author

Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

Cancer discovery·2013
Same author

BRAF as a therapeutic target: a patent review (2006 - 2012).

Expert opinion on therapeutic patents·2013
Same author

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

The New England journal of medicine·2012
Same author

Small molecule inhibitors of BRAF in clinical trials.

Bioorganic & medicinal chemistry letters·2012
Same author

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Cancer cell·2011
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Glufosfamide is an alkylating agent developed by Baxter Oncology.
  • It is a potential treatment for various cancers.

Purpose of the Study:

  • To evaluate glufosfamide as a cancer treatment.
  • To assess intrathecal administration of glufosfamide in Phase II trials.

Main Methods:

  • Phase II clinical trials were initiated by April 2000.
  • Intrathecal administration was a key method in one trial.

Main Results:

  • Glufosfamide reached Phase II trials.
  • The study focused on patients with carcinomatous meningioma.

Conclusions:

  • Glufosfamide shows potential as a cancer therapeutic.
  • Further investigation into its efficacy and administration routes is warranted.